Find a Clinical Trial

Showing 1 - 10 of 21 Trials
  • Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    e purpose of the study is to test the safety of an investigational study drug called BMS-986249. BMS-986249 will be given alone and in combination with nivolumab. These regimens will be compared to the treatment regimen of Nivolumab and Ipilimumab. This study will investigate how patients with advanced solid tumors tolerate these drugs. The study will identify the highest dose or most suitable dose of BMS-986249 alone and in combination with nivolumab. This is the first study in which BMS- 986249 will be given to humans. Are you Eligible? (Inclusion Criteria) Participant must have a solid...
  • Principal Investigator:

    David P. Horowitz, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    Early Phase I
    The purpose of this study is to find out if giving intravenous (IV) contrast (a liquid that helps with the visibility of organs and blood vessels that is given through the vein with the use of a hollow needle) during a Cone Beam Computed Tomography (CBCT- a type of computerized X-ray) can help people who have image guided radiation therapy (IGRT) for the treatment of abdominal and pelvic tumors. Are you Eligible? (Inclusion Criteria) For inclusion in this study subjects: 1. Must be greater than or equal to 18 years of age. 2. Will require image guided external beam radiotherapy to abdominal...
  • Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    The main purpose of this study is to test the safety of the investigational drug, BMS-986340, administered alone and in combination with nivolumab. This study will investigate how patients with selected advanced solid tumors tolerate these drugs to identify the highest tolerable dose or the most suitable dose, explore any changes in your tumor, and your general health after receiving multiple doses of BMS-986340 alone or together with nivolumab. BMS-986340 is an immunotherapy antibody and an investigational research drug. Investigational drugs are drugs that are not yet approved by the Food...
  • Principal Investigator:

    Matthew A. Ingham, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The goal of this study is to determine at what dose the study treatment (ASP9801) is safe and tolerated in study participants with cancer who have tumors that cannot be removed (unresectable) or have spread (metastasized) to a different part of the body. This will be done by enrolling small groups of participants to receive different doses of the study treatment, starting with a very small dose and gradually increasing. The study treatment is given by an injection directly into the tumor. The dose amount you receive will depend on the group you are assigned to. When the safe dose is...
  • Principal Investigator:

    Benjamin Izar, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The main purpose of this study is to determine the highest dose of STK-012 that can be given safely alone and in combination with a standard dose of pembrolizumab in subjects with advanced solid tumors, this will be assessed in the dose escalation phase of the study. In the dose expansion phase of the study, the highest dose of STK-012 that can be safely given in combination with pembrolizumab, as determined in the dose escalation phase, will be given to more people for further study.STK-012 is a modified (changed in the laboratory) form of a cytokine (protein) called interleukin-2 (IL-2)...
  • Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The primary purposes of this research study are to learn the safety and tolerability of the investigational drug, XmAb23104 for up to eight dose levels; if the XmAb23104 works in treating tumors like the one that you have; and the side effects from XmAb23104 that occur in order to find the maximum tolerated dose or recommended dose for treating your type of tumor. XmAb23104 is an investigational drug that is designed to activate your own cells to kill your tumor. XmAb23104 is an investigational drug in this study because it has not been approved by the U.S. Food and Drug Administration (FDA...
  • Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    This research study is studying a drug called AGEN2373 as a possible treatment for advanced cancer. The study drug targets cells that are a part of the body’s immune system to block a protein called anti-CD137 agonist antibody. Blocking this protein is believed to improve the ability of your immune system to fight your cancer. This drug has been tested in animals. This is the first time that the Study Drug will be given to humans. The study will also evaluate how the body breaks down the study drug (pharmacokinetics or “PK”) and what is the effect of the study drug on the...
  • Principal Investigator:

    Matthew A. Ingham, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    The purpose of this study is to test the safety of different doses of BA3011 and to find out what effects, good and/or bad, that it has on advanced solid tumor cancers that has tested positive for the AXL protein. AXL is a protein found on certain types of cancer cells. This research study will choose the dose amount that should be studied in the future and test the dose on a greater number of participants. The researchers will test how the body absorbs and processes different doses of BA3011 by taking blood samples.In addition to receiving BA3011, you will also be administered a granulocyte...
  • Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    The purpose of this study is to evaluate the safety profile of IDE196 (an “investigational” drug), in enrolled subjects to find out if it is safe and possibly helpful in patients with certain cancers such as: metastatic uveal melanoma, cutaneous melanoma or colorectal cancer or cancers with mutations in genes called GNAQ, GNA11, or PRKC fusion. The study may last for approximately 25 months and your participation will depend on how well you tolerate the study drug and your overall condition during the study. Are you Eligible? (Inclusion Criteria) Do you have a solid tumor(s) that...
  • Principal Investigator:

    Brian Henick, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you have an autoimmune disease such as rheumatoid arthritis, lupus, multiple sclerosis, or inflammatory bowel disease?...

Pages